The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral atypical antipsychotics (e.g., Otsuka / Lundbeck’s Rexulti and Allergan / Gedeon Richter / Recordati’s Vraylar / Reagila), and the intensifying competition among long-acting injectables (LAIs). Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for late-phase and recently approved therapies—including new oral atypical antipsychotics (e.g., Alkermes’s ALKS 3831), new LAIs (e.g., Indivior’s Perseris, Janssen’s paliperidone six-month depot, Teva’s TV-46000), and others (e.g., Intra-Cellular Therapies’ lumateperone, Minerva Neurosciences’ roluperidone, and Sunovion / Sumitomo Dainippon Pharma’s SEP-363856). Meanwhile, the potential of early- to mid-phase therapies for negative symptoms and cognitive impairment associated with schizophrenia, which are symptoms on which drug developers are increasingly focusing, remains to be seen.

Questions Answered

  • What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
  • What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?
  • What are the biggest areas of unmet need? What is the line-up of late-phase emerging therapies with the potential to fulfill these needs?
  • What would key late-phase emerging therapies need to demonstrate to compete effectively in this crowded market?

Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Geographies: United States, EU5, Japan.

Primary research: 35 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.

Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2028, segmented by brands / generics.

Emerging therapies: Phase III / PR: 8 drugs. Coverage of select Phase II and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Schizophrenia Key Findings November 2019
    • Key Updates
      • November 2019
      • September 2019
      • June 2019
      • December 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Schizophrenia?
        • What Factors Are Constraining the Market for Schizophrenia?
      • Drug-Class-Specific Trends
        • Atypical Antipsychotics: Orals
        • Atypical Antipsychotics: LAIs
        • Atypical Antipsychotics: Short-Acting IMs
        • Atypical Antipsychotics: Other Formulations
        • Typical Antipsychotics: Orals, LAIs, Short-Acting IMs, and Other Formulations
        • Mixed Neurotransmitter Modulators
        • 5-HT2A / Sigma2 Receptor Antagonists
        • 5-HT1A / TAAR1 Agonists
    • Forecast
      • Market Forecast Assumptions - Schizophrenia (2018-2028) - November 2019
      • Market Forecast Dashboard - Schizophrenia (2018-2028) - November 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Genetic Factors
      • Environmental Factors
      • Key Pathways and Drug Targets
      • Abnormalities in Brain Structure and Function
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Lifetime Prevalent Cases of Schizophrenia
        • Symptom Status Cases
        • Drug-Treated Cases of Schizophrenia
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Atypical Antipsychotics: Orals, LAIs, Short-Acting IMs, and Other Formulations
        • Typical Antipsychotics: Orals, LAIs, Short-Acting IMs, and Other Formulations
        • Therapies for CIAS
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Schizophrenia
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Atypical Antipsychotics: Orals
        • Atypical Antipsychotics: LAIs
        • Mixed Neurotransmitter Modulators
        • 5-HT2A / Sigma2 Receptor Antagonists
        • 5-HT1A / TAAR1 Agonists
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Schizophrenia
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Methodology
        • Market Forecast Assumptions File
        • Bottom-Up Forecasting Overview
        • Bottom-Up Forecast Assumptions
        • Primary Market Research
    • Appendix
      • Schizophrenia Bibliography

Author(s): Himanshu Jain, M.S. Pharm; Swarali Tadwalkar, MPH

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis. Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.

Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space. Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.


Related Reports

Bipolar Disorder | Special Topics | Special Topics: Agitation in bipolar and schizophrenia (US)

COMING SOON Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manife...

View Details